Learn more about Elsevier’s Drug Patient Education today! Empower and engage your patients to use medication safely.
BEBTELOVIMAB (beb te loe vi mab) treats COVID-19. It may decrease the risk of developing severe symptoms of COVID-19. It may also decrease the chance of going to the hospital. This medication is not approved by the FDA. The FDA has authorized emergency use of this medication during the COVID-19 pandemic.
This medication is injected into a vein. It is given by your care team in a hospital or clinic setting.
Talk to your care team about the use of this medication in children. While it may be given to children as young as 12 years, precautions do apply.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
This medication is given in a hospital or clinic. It will not be stored at home.
They need to know if you have any of these conditions:
This does not apply. This medication is not for regular use.
Your condition will be monitored carefully while you are receiving this medication. Visit your care team for regular checks on your progress. Tell your care team if your symptoms do not start to get better or if they get worse.
After receiving this medication, you may need to wait before getting the COVID-19 vaccine. Talk to your care team about when you can receive the COVID-19 vaccine.
Cookies are used by this site. To decline or learn more, visit our cookies page.